The goal of this observational study is to explore the influence of Covid-19 infectionand risk factors of severe outcomes in vulnerable population including patients withchronic liver disease, malignant tumor, autoimmune disease, medical staff.The main questions it aims to answer are: 1. The clinical characteristics of vulnerable population after Covid-19 infection. 2. Risk factors for severe illness in vulnerable groups after infection with the Covid-19. 3. The impact of Covid-19 infection on the progression of underlying diseases.Information of participants will be collected such as gender, age, underlying diseases,medication status, vaccination status, clinical and biochemical indicators.Researchers will compare the mild and severe outcomes after Covid-19 infection toidentify the "truly vulnerable" population and explore the potential mechanism andintervention for these population.
Not Provided
Other: underling disease
Nowadays Covid-19 virus has become milder than before however severe outcomes still
happen in people with underlying diseases after infection.
For example, previous research indicated cirrhosis was an independent predictor for
COVID-19 mortality.
More efforts shoud be make to explore the association between underlying diseases and
severe COVID-19.
Inclusion Criteria:
1. Sign the informed consent form before enrollment, and be able to complete the
research according to the requirements of the research protocol.
2. Enrolled patients need to have basic diseases, including chronic liver disease,
chronic kidney disease, chronic lung disease, solid tumors, AIDS, rheumatic immune
diseases, diabetes, etc.
3. When entering the group, patients with new crowns need to be confirmed by evidence
of a positive test for new coronavirus nucleic acid (CT value <35) or a positive
test for new coronavirus antigen.
Exclusion Criteria:
1. Participate in clinical trials of other investigational drugs or medical devices
within 3 months before screening, and take experimental drugs or use medical
devices.
2. Positive pregnancy test during lactation or screening period.
3. Subjects who, in the investigator's opinion, have other factors that are not
suitable for participating in this study.
Not Provided
Ke Qiu, MD.
+86 18523571923
535424396@qq.com
Peng Hu, PhD.
+86 13608338064
hp_cq@163.com
Peng Hu, PhD., Study Director
The Second Affiliated Hospital of Chongqing Medical University